1. Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist

3. Introduction/Overview

4. Linkage Between Elevated Glucose and CV Disease/Events: Correlation or Causality?

5. Lowering HbA1c Reduces the Risk of Microvascular Complications

6. CV Improvements and Novel Glucose-Lowering Agents

7. LEADER: Primary Outcome*

8. LEADER TRIAL: Time to Composite Endpoint (Macroalbuminuria, Doubling of Serum Creatinine, ESRD, Renal Death)

9. SAVOR-TIMI, EXAMINE, TECOS: Topline Results

11. SUSTAIN-6 (Semaglutide): Primary Outcome Results

12. EMPA-REG: Primary Outcome (3-point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

13. Characteristics of GLP-RAs

14. EMPA-REG: Primary Outcome and CANVAS CV Results

15. MACE Endpoints: LEADER and SUSTAIN-6

16. What Explains the Macro- and Microvascular Improvements Observed in LEADER?

17. LEADER Results: Hypoglycemia

18. GLP-1 RAs and Experimental Models of CVD

19. EMPA-REG: Hospitalization for HF

20. Kidney Damage and SGLT2 Inhibitors

21. Guidelines’ Changes as a Result of CV Outcomes Trial Findings

22. Risk Factor Reduction With Empagliflozin and Liraglutide

23. Clear-Cut Clinical Roles for Liraglutide and Empagliflozin

24. DECLARE TIMI-58: Dapagliflozin Effect on CardiovascuLAR Events: Study Design

25. Patient Selection With Cardiorenal Protective Glucose-Lowering Agents

26. Patient Preferences: Injection vs Increased Urinary Frequency

27. Summary and Conclusions